Form 4: MBX Biosciences Insider Ali Behbahani Reports Beneficial Ownership Changes After IPO

Ali Behbahani, a director and indirect owner of MBX Biosciences, reports changes in beneficial ownership following the company's initial public offering on September 16, 2024, including the conversion of preferred stock into common stock and the purchase of additional common stock.

Summary

• On September 16, 2024, Ali Behbahani, a director of MBX Biosciences, reported changes in beneficial ownership of the company's stock.
• The changes are primarily due to the conversion of Series A and Series B Convertible Preferred Stock into common stock immediately prior to the closing of MBX Biosciences' initial public offering (IPO).
• 1,023,103 shares of Common Stock were acquired through the conversion of Series A Convertible Preferred Stock.
• 2,091,383 shares of Common Stock were acquired through the conversion of Series B Convertible Preferred Stock.
• Behbahani also purchased 500,000 shares of Common Stock at a price of $16 per share.
• Following these transactions, Behbahani indirectly beneficially owns 3,614,486 shares of Common Stock.
• The reporting person disclaims beneficial ownership of the securities held by NEA 17 in which the Reporting Person has no pecuniary interest.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions related to an IPO, which is generally a positive event. The insider's purchase of additional shares at $16 indicates confidence in the company's future.

Positives

• The conversion of preferred stock to common stock simplifies the capital structure of MBX Biosciences following its IPO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests with management.

Comparison to Industry Standards

• Form 4 filings are a standard regulatory requirement for publicly traded companies in the United States, ensuring transparency in insider trading activities.
• Similar filings are made by insiders at companies like Eli Lilly and Novo Nordisk, providing investors with insights into executive and director stock transactions.

Stakeholder Impact

• The conversion of preferred stock to common stock and insider purchases can influence investor sentiment and potentially impact the stock price.

Key Dates